Integra LifeSciences Shares Dropped: What You Need to Know (IART)

Integra LifeSciences Shares Dropped: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of medical device maker Integra LifeSciences (Nasdaq: IART ) fell 14% today after the company released earnings and cut its full-year forecast.

So what: Third-quarter results weren't bad at all and actually beat expectations slightly. Revenue was up 8% to $202.2 million and earnings per share of $0.77 beat expectations by a penny.

But the company cut its full-year adjusted earnings per share forecast to $2.88-$2.96, and the market didn't see that as a positive sign.

Now what: The guidance range was only lowered by $0.04 at the bottom end, and analysts had expected $2.93 per share, about smack in the middle of the updated range, so the company isn't exactly out of line. The company also didn't change revenue guidance, something it would have done if the business was in any sort of real trouble. I'm seeing this drop as a bit of an overreaction by the market, which could provide a nice entry point for investors looking to buy shares.

Interested in more info on Integra LifeSciences? Add it to your watchlist by clicking here.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.